NASDAQ:ASMB • US0453962070
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ASSEMBLY BIOSCIENCES INC (ASMB).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-12-22 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-11-20 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-10-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-09-24 | JMP Securities | Initiate | Market Outperform |
| 2025-09-08 | Guggenheim | Maintains | Buy -> Buy |
| 2025-03-25 | Guggenheim | Initiate | Buy |
| 2025-03-24 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-12-27 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-09-24 | HC Wainwright & Co. | Reiterate | Neutral |
| 2024-09-20 | Jefferies | Upgrade | Hold -> Buy |
| 2024-06-20 | HC Wainwright & Co. | Reiterate | Neutral |
| 2024-06-13 | HC Wainwright & Co. | Reiterate | Neutral |
| 2024-04-01 | HC Wainwright & Co. | Reiterate | Neutral |
| 2023-03-24 | HC Wainwright & Co. | Maintains | Neutral |
| 2022-11-16 | Mizuho | Maintains | Buy |
| 2022-10-24 | Truist Securities | Downgrade | Buy -> Hold |
| 2021-09-13 | HC Wainwright & Co. | Initiate | Neutral |
| 2021-09-02 | William Blair | Downgrade | Outperform -> Market Perform |
| 2021-05-10 | SVB Leerink | Maintains | Market Perform |
| 2021-03-23 | SVB Leerink | Downgrade | Outperform -> Market Perform |
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | -100.00% | 7.163M | 28.52M 298.16% | 38.027M 33.33% | 22.278M -41.42% | 83.487M 274.75% | 29.036M -65.22% | 65.994M 127.28% | 61.9M -6.20% | 118.67M 91.71% | 214.47M 80.73% | 286.08M 33.39% | |
| EBITDA YoY % growth | -92.519M -0.64% | -64.196M 30.61% | -45.291M 29.45% | -44.523M 1.70% | -47.175M -5.96% | 32.691M 169.30% | -35.394M -208.27% | 73.644M 308.07% | 21.012M -71.47% | -18.87M -189.81% | 54.876M 390.81% | N/A | |
| EBIT YoY % growth | -93.017M -0.67% | -64.646M 30.50% | -45.42M 29.74% | -44.619M 1.76% | -61.495M -37.82% | 42.243M 168.69% | -37.15M -187.94% | 9.506M 125.59% | -31.355M -429.84% | -14.102M 55.03% | 99.713M 807.11% | 144.1M 44.51% | |
| Operating Margin | N/A | -902.50% | -159.26% | -117.34% | -276.04% | 50.60% | -127.95% | 14.40% | -50.65% | -11.88% | 46.49% | 50.37% | |
| EPS YoY % growth | -23.16 4.93% | -13.67 40.98% | -6.72 50.84% | -3.63 45.91% | -3.55 2.25% | 2.02 156.84% | -3.05 -251.01% | -1.91 37.35% | -3.04 -59.08% | -2.72 10.40% | -0.11 96.07% | 1.63 1,623.81% |
All data in USD
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.66 57.77% | -0.74 36.79% | -0.86 35.58% | -1.10 -53.00% | -1.42 -114.62% |
| Revenue Q2Q % growth | 7.571M 2.91% | 9.486M 0.71% | 7.956M -17.35% | 10.812M 0.21% | 408K -94.61% |
| EBITDA Q2Q % growth | -9.996M 12.34% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -11.65M -1.02% | -14.484M -45.70% | -20.094M -81.14% | -28.356M -160.55% | -30.396M -160.92% |
All data in USD
10 analysts have analysed ASMB and the average price target is 46.67 USD. This implies a price increase of 65.98% is expected in the next year compared to the current price of 28.115.
ASSEMBLY BIOSCIENCES INC (ASMB) will report earnings on 2026-03-18, after the market close.
The consensus EPS estimate for the next earnings of ASSEMBLY BIOSCIENCES INC (ASMB) is -0.66 USD and the consensus revenue estimate is 7.57M USD.
The consensus rating for ASSEMBLY BIOSCIENCES INC (ASMB) is 86 / 100 . This indicates that analysts generally have a positive outlook on the stock.